Evotec and Novo Nordisk have announced the selection of three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and the Joslin Diabetes Center for further development within LAB eN², an initiative focused on cardiometabolic diseases.
LAB eN² is also expanding to incorporate five additional prestigious academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, the Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai, Evotec mentioned in a recent statement.
Originally launched in September 2023 in collaboration with Harvard University, Mass General Brigham, the Yale School of Medicine, and Beth Israel Deaconess Medical Center, LAB eN² will now benefit from contributions by researchers at Boston Children's Hospital, Boston University, Johns Hopkins University, the Joslin Diabetes Center, and Icahn Mount Sinai, who can submit their projects for consideration.
By accessing Evotec's comprehensive R&D platform combined with Novo Nordisk's extensive expertise in disease understanding, LAB eN² offers funding and support to develop a drug discovery program and advance the identification of a therapeutic candidate across various therapeutic modalities.
